Does Rallies show 13F holders for LTRN?

Yes. Rallies tracks hedge fund and 13F ownership data for LTRN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is LTRN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LTRN. It does not provide personalized investment advice.

LTRN (Lantern Pharma Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Lantern Pharma Inc. Common Stock (LTRN) is a publicly traded Healthcare sector company. As of May 21, 2026, LTRN trades at $3.20 with a market cap of $38.28M and a P/E ratio of -2.01. LTRN moved +2.91% today. Year to date, LTRN is -2.46%; over the trailing twelve months it is -8.91%. Its 52-week range spans $1.11 to $6.12. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces LTRN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns LTRN stock?

Hedge funds tracked by Rallies that own LTRN include Renaissance Technologies, Citadel Advisors, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Lantern Pharma Inc. Common Stock.

LTRN Key Metrics

Key financial metrics for LTRN
Metric	Value
Price	$3.20
Market Cap	$38.28M
P/E Ratio	-2.01
EPS	$-1.57
Dividend Yield	0.00%
52-Week High	$6.12
52-Week Low	$1.11
Volume	404
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-17.12M
Gross Margin	0.00%

Top Hedge Funds Holding LTRN

Renaissance Technologies holds 87.30K shares of LTRN, changed +3.93% as of Dec 31, 2024.
Citadel Advisors holds 37.59K shares of LTRN, changed +1645.80% as of Dec 31, 2024.
Two Sigma holds 16.55K shares of LTRN, changed -51.82% as of Dec 31, 2024.

Latest LTRN News

Lantern Pharma Cuts Costs 19%, Posts $17.1M Net Loss and Secures FDA IND — Apr 3, 2026
Lantern Pharma Secures Third LP-284 Orphan Drug Status and Opens AI Hub — Feb 12, 2026

Recent LTRN Insider Trades

Schalop Lee Troy bought 48.54K (~$100.00K) on May 12, 2026.
KEYSER D JEFFREY bought 48.54K (~$100.00K) on May 12, 2026.
Fletcher Aaron G.L. sold 7.21K (~$22.27K) on Jun 13, 2025.

LTRN Analyst Consensus

1 analysts cover LTRN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.

Common questions about LTRN

Who owns LTRN stock?: Hedge funds tracked by Rallies that own LTRN include Renaissance Technologies, Citadel Advisors, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Lantern Pharma Inc. Common Stock.
Does Rallies show 13F holders for LTRN?: Yes. Rallies tracks hedge fund and 13F ownership data for LTRN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is LTRN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LTRN. It does not provide personalized investment advice.